Overview

Join us for an event that unites community-based providers and academic oncologists, all dedicated to enhancing the care and outcomes of patients with hematologic malignancies. This activity will explore the latest treatment options and medical advancements aimed at reducing cancer-related deaths. You’ll gain insights into groundbreaking therapies like CAR T-cell therapy, novel immunotherapies, and targeted agents that represent the forefront of managing both newly diagnosed and relapsed blood cancers.

Stay informed with the latest scientific updates and innovative strategies that directly impact your practice. Participants will engage in discussions about rapidly evolving treatment landscapes, evaluate critical considerations for sequencing novel agents, and refine practice paradigms that elevate patient care across all treatment settings.

This is your chance to enhance your knowledge of best practices for treating hematologic cancers while learning when to refer patients for specialized quaternary care and clinical trial opportunities. Don’t miss out on this chance to stay ahead in your field—register today to secure your spot and transform your approach to patient management!

Learning Objectives

After this activity, participants will be able to:

• Recall international trends in the care of hematologic malignancies;
• Identify the emerging treatment strategies, the role of targeted agents in therapeutic paradigms for patients with myeloid malignancies, and available clinical trial options and other approaches to patients with relapsed/refractory disease;
• State the optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed/refractory disease;
• Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases including newly approved therapeutic classes;
• Discuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, as well as bispecific antibodies with varied therapeutic targets;
• Illustrate how cutting-edge data presented at the 2024 Annual Meeting of the American Society of Hematology can apply to clinical practice;
• Interpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies and its place in evolving hematologic malignancy treatment standards;
• Evaluate the available treatments to care for patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for evidence-based care of both newly diagnosed and relapsed/refractory cases.

Target Audience

This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.

Accreditation

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.